Effectiveness, safety, and tolerability of galcanezumab in a real-life setting in patients with migraine in Italy (the GARLIT study)
Neurol Sci
.
2020 Dec;41(Suppl 2):487-488.
doi: 10.1007/s10072-020-04669-y.
Authors
Fabrizio Vernieri
1
,
Claudia Altamura
2
,
Cinzia Aurilia
3
,
Nicoletta Brunelli
2
,
Gabriella Egeo
3
,
Luisa Fofi
3
,
Carmelina Maria Costa
2
,
Adriana Fallacara
2
,
Valentina Favoni
4
,
Giulia Pierangeli
4
,
Marco Aguggia
5
,
Davide Bertuzzo
5
,
Maria Albanese
6
,
Paola Di Fiore
7
,
Fabio Frediani
7
,
Sabina Cevoli
4
,
Piero Barbanti
3
Affiliations
1
Unità Cefalee e Neurosonologia, Policlinico Universitario Campus Bio-Medico, Rome, Italy. f.vernieri@unicampus.it.
2
Unità Cefalee e Neurosonologia, Policlinico Universitario Campus Bio-Medico, Rome, Italy.
3
Unità Cefalee e Dolore, IRCCS San Raffaele Pisana, Rome, Italy.
4
IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.
5
SOC Neurologia e Stroke Unit, Ospedale Cardinal Massaia, Asti, Italy.
6
Centro Cefalee, U.O.C di Neurologia, Policlinico Tor Vergata, Rome, Italy.
7
Centro Cefalee, S. Carlo Borromeo, Milan, Italy.
PMID:
32845481
DOI:
10.1007/s10072-020-04669-y
No abstract available
MeSH terms
Antibodies, Monoclonal, Humanized* / adverse effects
Humans
Italy
Migraine Disorders* / drug therapy
Substances
Antibodies, Monoclonal, Humanized
galcanezumab